There are many types of Non-small cell lung cancer treatment options, and determining the right options important. Each treatment option is designed for a particular type of cancer and the needs of the individual. Surgical options include the removal of a part of lung and subsequent chemotherapy. If the cancer is limited to the lung and hasn't spread to nearby structures, it can often be cured without surgery. Other treatment options may include radiation or chemotherapy. In some cases, additional treatments may be prescribed before or after surgery to reduce the risk of a recurrence. Induction therapy, also known as preoperative chemotherapy, may be administered before the surgery to reduce the risk of cancer recurrence. A biopsy is another option for non-small cell lung cancer treatment. This procedure involves collecting a small sample of tissue or fluid from the lungs and then studying it under a microscope. There are various methods of collecting this sample, including fine needle aspiration and thoracentesis. The appropriate biopsy method depends on age, symptoms, and overall health of the patient. Two types of chemotherapy regimens have been shown to be effective against non-small cell lung cancer. A double-tumor regimen combined with an anti-VEGF monoclonal antibody, called bevacizumab, led to better overall survival in the study. However, multiple factors may affect the prognosis, and the treatments that work for one person may not work for another. Several studies have indicated that chemotherapy regimens based on platinum-based doublets do not have any efficacy in patients with non-small-cell lung cancer. Advanced forms of Non-Small Cell Lung Cancer Treatment are immunotherapy, targeted therapies, and chemotherapy. In Bodor et al1, these first-line treatments for NSCLC without driver mutations are discussed. However, despite recent advances, some patients still need to wait until they reach stage III to receive treatment. These advanced treatments are not without side effects and can be costly. EGFR-TKI therapy is another option for non-small cell lung cancer treatment. In this treatment, targeted therapies penetrate the brain to kill cancer cells. These therapies may be useful for treating brain metastases as well as other subtypes of lung cancer. Immunotherapy with pembrolizumab may also be considered in some patients. These drugs may be able to target the EGFR gene in the brain. While immunotherapy may not cure this cancer, it is an effective way to extend a patient's lifespan. Recent advances in immunotherapy for lung cancer include tyrosine kinase inhibitors and chimeric antigen receptor T cells. While chimeric antigen receptor T cells are promising candidates, the availability and safety of these agents should be considered when choosing the right treatment for the patient. In the meantime, immunotherapy may be the answer for advanced lung cancer patients. Among the first-line treatments for advanced non-small cell lung cancer, crizotinib is an effective option. However, this treatment has a high rate of disease progression, with many patients requiring relapse within 12 months. However, this therapy does not work in all patients, as one third of ALK-rearranged NSCLC suffer from disease progression or ALK amplification. Another option for NSCLC is ceritinib, a small-molecule oral tyrosine kinase inhibitor of ALK. This drug is 20-fold more effective than crizotinib, however, it has no tumor activity against MET.
0 Comments
Leave a Reply. |
Categories
All
|